Companies › Qurient
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Respiratory; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Adrixetinib (Q702) Axl/Mer/CSF1R selective tyrosine kinase inhibitor | AXL, MER, CSF1R | Phase 1 | Esophageal Cancer; Chronic Graft-Versus-Host Disease | Dec 2027 |
| Q901 Highly selective CDK7 inhibitor | CDK7 | Phase 1 | Advanced Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05394103 | Q901 | Phase 1 | Advanced Cancer | Oncology | Dec 2025 |
| NCT05438420 | Adrixetinib (Q702) | Phase 1 | Esophageal Cancer | Oncology | Dec 2027 |
| NCT07138196 | Adrixetinib (Q702) | Phase 1 | Chronic Graft-Versus-Host Disease | Respiratory | Oct 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.